Navigation Links
Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission

The pharmaceutical company Starpharma saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent transmission of HIV. // The company even signed a $20 million (US) contract with the US National Institute of Allergy and Infectious Diseases, an integral part of the National Institute of Health.

'There are currently no approved products for the prevention of HIV infection. The FDA recognizes the potential of Vivagel to address this unmet medical need. Vivagel's new drug application will now receive priority review, which has a shorter assessment time. The early review is expected to shorten FDA's approval time significantly', said John Raff, Chief executive of Starpharma.

It is further hoped that the FDA’s initiative to accelerate the approval process would contribute to the development of the company, in the opinion of Jackie Fairley, Chief operating officer, Starpharma.

It was anticipated that the approval and commercial use of the drug would take about 13 months. With this green signal from the FDA, it could be materialized in less than 6 or 7 months according to official reports.

The product is primarily targeted at women, and would help them prevent contracting sexually transmitted diseases such as genital herpes, HIV and so on. The drug, a vaginal formulation has to be topically applied prior to intercourse and would function as a chemical barrier against various infections.

'Vivagel is not a treatment for HIV. The gel is used topically prior to sexual intercourse to prevent the women from becoming infected with HIV, genital herpes and other sexually transmitted diseases', said Dr Fairley.

AIDS is increasingly becoming a global burden, with nearly 40 million people afflicted with the disease worldwide. The number of genital herpes and AIDS/HIV in Australia is estimated to be 3.4 million and 15, 000 respectively. This is of great importan ce as individuals with genital herpes have an increased risk (5 to 7 times greater risk) of contracting the AIDS virus.

A Phase I clinical trial involving the new drug is expected to be launched soon. If the results are satisfactory, the drug would be approved for use in the US, Australia and Europe by the end of 2008.


'"/>




Related medicine news :

1. Kirin Develops a Cure for Bird Flu
2. Hungary Develops New Bird Flu Vaccine
3. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
4. Samsung Develops Device to Measure Body Fat
5. India Develops Test for Diagnosis of Deadly Livestock Disease
6. Mouth Cancer Develops In Two Different Ways
7. John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases
8. Researcher Develops Sensor to Detect E.coli
9. Australian Firm Develops Low Glycaemic Sugar to Prevent Diabetes
10. US Company Develops Better Weight Reduction Pill
11. Rhode Island Biotechnology Company Develops Tularemia Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Pa. (PRWEB) , ... October 13, 2017 , ... While ... dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. ... to medication in darkness or restricted lighting. As such, it eliminates the need to ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology: